CClinicalTrials.gg
CompletedNCT05994781Updated Aug 22, 2023

A Prospective Researcher-led Clinical Study of Neopep-S-based EasyDew MD Regen Cream

An interventional study of EasyDew MD regen cram in Skin Lesion, sponsored by Eun-ji Kim. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-22.

Sponsored by Eun-ji Kim · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Nov 2022, registered Aug 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

This clinical study is conducted prospectively for 3 months after medical device treatment.

It is a comparative clinical study of the leading control group.

Read the detailed description

Subjects need tissue transplantation to repair skin defects, so partial layer skin transplantation is performed. After proceeding, the patient is no longer subject to exudation. Subjects (and/or legal representatives) have agreed in writing to participate in the clinical study Perform a post-screening test.

Evaluating the screening test results, meeting the selection criteria, and meeting the exclusion criteria those who do not are registered for clinical research.

In the case of the study group among the subjects of the clinical study, whether partial layer skin transplantation was performed or not, Apply an appropriate amount of EasyDew MD Regen Cream twice a day (morning and evening) and can be absorbed well.

The control group is a non-treatment group, and for 3 months after the procedure. General moisturizers that have been used or will be used are available. The control group's Moisturizer is recommended twice a day (morning and evening) on whether skin grafts are collected or not Apply and allow good absorption. After applying medical devices and moisturizers for clinical research, the progress will be observed for 3 months, Subjects are a screening visit (Visit1), the day of medical device application (Visit2), and after medical device application.

Visit the research institution regularly for one month (Visit3) and three months after application (Visit4) for validity and it will be evaluated for safety.

02

Conditions studied

  • Skin Lesion
03

In context

Lead sponsor

Eun-ji Kim is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • adults over the age of 19
  • Subjects with partial layer skin transplantation
  • There is no evidence of infection in the skin transplant process, and exudate is no longer present a person who does not arise
  • Decide to participate in this clinical study arbitrarily and in the written informed consent a person

Exclusion criteria

Exclusion Criteria:

  • showing signs of infection requiring antibiotic administration throughout the body or skin transplantation Case
  • In situations where the requirements of a clinical study cannot be complied with
  • When the researcher's judgment determines that the participation of the study is inappropriate (e.g. Kelloid personality)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • No intervention
    No treatment

    The control group is a non-treatment group, and for 3 months after the procedure, general moisturizers that have been used or will be used are available.

  • Experimental
    Treatment

    In the case of the study group among the subjects of the clinical study, The experimental group apply an appropriate amount of EasyDew MD Regen Cream twice a day (morning and evening) and can be absorbed well.

    Device: EasyDew MD regen cram

Interventions

  • DeviceEasyDew MD regen cram

    No intervention

    Also known as: No treatment

06

What researchers measure

Primary outcomes

  1. TEWL score

    Transepidermal water loss score/ No range of upper and lower score, the lower is best

    Time frame: Before, after one month after application, 3 month after application

Secondary outcomes

  1. Investigator Global Assessment scale

    Assess the patient's overall condition /lowest 0 score ( best score) to highest 30 score( worst score)

    Time frame: Before, after one month after application, 3 month after application

  2. Dermatology Life Quality Index

    Assess patient quality of life / lowest 0 score ( best score) to highest 4 score( worst score)

    Time frame: Before, after one month after application, 3 month after application

  3. itching scale

    Evaluate the Itching scale / lowest 1 score ( best score) to highest 5 score( worst score)

    Time frame: Before, after one month after application, 3 month after application

  4. VSS

    Vancouver Scar Scale/ No range of upper and lower score, the lower is best

    Time frame: Before, after one month after application, 3 month after application

07

Study locations

1 site
  • Ajou University Hospital
    Gyeonggi-do, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05994781
Lead sponsor
Eun-ji Kim
Responsible party
Eun-ji Kim (Clinical Trial Manager, CGBio Inc.) — Sponsor-investigator
First posted
Aug 16, 2023
Start date
Nov 11, 2022
Primary completion
Jun 27, 2023
Completion
Jun 30, 2023
Last update
Aug 22, 2023

Study contacts

Jihye Lee, Master
study director · CGBio Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion